wjpmr, 2024, 10(8), 51-57

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

DRUG RESISTANCE DEVELOPMENT IN EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS (XDR-TB): MECHANISMS, CHALLENGES, AND FUTURE PERSPECTIVES

Rathod Ashwin Datta[1*], Shaikh Sameer Shaikh Farid[2], Kartik G. Jadhav[3] and Syed Nabeel Ahmad[4]

[1,2,3,4]Pharm D., Swami Ramanand Teerth Marathwada University, Nanded.

***Corresponding Author: Rathod Ashwin Datta**

Pharm D., Swami Ramanand Teerth Marathwada University, Nanded.

Email ID: rathodashvin950@gmail.com

Article Received on 31/05/2024 **Article Revised on 21/06/2024** **Article Accepted on 11/07/2024**

ABSTRACT

Because it is resistant to both first- and second-line anti-tuberculosis medications, extensively drug-resistant tuberculosis (XDR-TB) represents a serious danger to international health. The processes behind the development of medication resistance in XDR-TB are summarized in this study, with a particular emphasis on acquired resistance mechanisms and genetic changes that reduce the effectiveness of treatment. The article highlights several difficulties in the clinical management of XDR-TB, such as the lack of adequate diagnostic tools, complicated treatment plans that are toxic, and inadequate infrastructure in healthcare systems. Promising future prospects are examined despite these obstacles, including developments in molecular diagnostics for quick drug susceptibility testing, the creation of novel anti-tuberculosis drugs, and creative treatment approaches meant to enhance patient outcomes and lower transmission rates. It will need coordinated efforts from the healthcare sectors, international cooperation, and ongoing investment in R&D to address these complex concerns. Through the application of comprehensive tactics and improved comprehension of drug resistance processes, we can lessen the effects of XDR-TB and get closer to meeting global tuberculosis control objectives.

KEYWORDS: XDR-TB, drug resistance, tuberculosis, antimicrobial resistance, treatment challenges.

INTRODUTION

A significant subgroup of tuberculosis (TB) infections is known as extensively drug-resistant tuberculosis (XDR-TB) , which is defined by resistance to at least one of the three injectable second-line drugs (amikacin, kanamycin, or capreomycin), a fluoroquinolone, and the two most effective first-line medications, isoniazid and rifampicin. Because of this resistance pattern, treating XDR-TB with traditional anti-TB treatments is very challenging, necessitating the use of second-line therapies, which are frequently more toxic and less effective.

Multidrug-resistant tuberculosis (MDR-TB), in which resistance to first-line medications develops initially and then resistance to second-line treatments through genetic changes and bacterial adaptability, is the main cause of extended or inappropriate treatment-associated tuberculosis (XDR-TB). Limited treatment choices, difficulties in accurately diagnosing the disease, and socioeconomic factors that lead to treatment non-compliance and transmission all contribute to the global spread of XDR-TB.

A multimodal strategy that incorporates enhanced public health initiatives, innovative treatment agents, and better diagnostics is necessary for the effective management of XDR-TB. To lessen its effects on worldwide health and meet TB control goals, it is crucial to comprehend the meaning and traits of XDR-TB.[1,2]

Global Prevalence

XDR-TB is a major worldwide health problem, with instances documented in almost every nation. According to current estimates, 9% of cases of multidrug-resistant tuberculosis (MDR-TB) worldwide are caused by XDR-TB.

Regional Distribution

The prevalence of XDR-TB differs by location. In areas of Eastern Europe, Central Asia, and Africa with greater prevalence of tuberculosis and multidrug-resistant tuberculosis, reports of it are more frequent. Several former Soviet Union nations, India, China, Russia, and South Africa are among the specific nations having significant XDR-TB burdens.

Incidence and Mortality

Annual variations in the prevalence of XDR-TB cases are caused by factors such as treatment accessibility, diagnostic capacity, and healthcare infrastructure.

Because there are fewer treatment choices and a greater likelihood of treatment failure for XDR-TB, the mortality rates are much higher than those for drug-sensitive TB.[3,4,5]

DRUG RESISTANCE IN TUBERCULOSIS

Several intricate processes, which can exist alone or in combination within the same strain of Mycobacterium tuberculosis, give rise to drug resistance in tuberculosis (TB). It is essential to comprehend these mechanisms in order to create treatment plans that work.

1. **Genetic Mutations**
   - Genetic mutations in certain genes that encode drug targets or enzymes involved in drug activation or metabolism are the most frequent cause of treatment resistance in tuberculosis.
   - Mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, frequently lead to ribampicin (RIF) resistance. These mutations change rifampicin's binding site, which lessens the drug's potency.
   - One possible cause of isoniazid (INH) resistance is mutations in genes like katG and inhA. While mutations in inhA alter INH's binding to its target, the enoyl-ACP reductase enzyme, changes in katG lessen INH's activation.

2. **Target Modification**
   - Certain mutations change the medication targets such that antibiotics can less effectively block them. DNA gyrase, the target of fluoroquinolone antibiotics, is altered by mutations in the gyrA and gyrB genes, which give resistance to these drugs.

3. **Drug Inactivation**
   - Enzymes produced by mycobacteria can alter or break down medications before they have a chance to have an antibacterial impact. As an illustration, the catalytic conversion of the prodrug to its active form by the KatG enzyme renders INH inactive. INH resistance can result from katG mutations that lessen its activation.

4. **Efflux Pumps**
   - Mycobacteria have the ability to produce efflux pumps, which aggressively pump medications out of the bacterial cell to lower their effectiveness and intracellular concentration. Efflux pumps, which pump medications out of the bacterial cell before they may reach effective concentrations, such the Rv1258c protein in Mycobacterium TB, contribute to resistance against various treatments.

5. **Bacterial Persistence**
   - Even after receiving antibiotic therapy, non-replicating or slowly replicating microorganisms in TB lesions can persist. Due to their decreased medication susceptibility, these bacteria can become resistant to treatments and cause treatment failure. As a result of this persistence, drug-resistant bacterial subpopulations may form, making treatment even more difficult.

6. **Mixed Infections and Compartmentalization**
   - Mixed infections, in which susceptible and resistant strains coexist, might result from inadequate treatment or noncompliance. Antibiotics can exert selection pressure on resistant bacteria, causing them to multiply. Drug penetration may be restricted in some host compartments, such as granulomas, where tuberculosis germs can live. This may lead to less than ideal drug exposure and promote the emergence of resistance.

7. **Biofilm Formation**
   - Bacterial populations encased in a protective matrix are known as biofilms, and they can be formed by TB bacteria. Because biofilms change the physiology of the bacteria and reduce medication penetration, they can increase resistance to antibiotics. Compared to their planktonic counterparts, bacteria in biofilms are frequently more resistant to antibiotics, making treatment more difficult.

Knowing these mechanisms highlights the importance of combination therapy, which targets several pathways at once, following treatment guidelines to stop resistance from developing, and continuous research into new medications and approaches to treatment that can get around these resistance mechanisms.[6,7,8]

DEVELOPING DRUG RESISTANCE IN EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS (XDR-TB)

Extensively drug-resistant tuberculosis (XDR-TB) is characterized by complicated processes that compromise public health initiatives and treatment efficacy. Tuberculosis resistant to isoniazid and rifampicin, any fluoroquinolone, and at least one of the three injectable second-line medications (amikacin, kanamycin, or capreomycin) is known as XDR-TB. It is essential to comprehend the processes underlying this resistance in order to create efficient treatment plans and slow its spread.

1. **Genetic Mutations and Mechanisms of Resistance**
   - **Resistance to Isoniazid (INH)**: The main cause of isoniazid resistance is mutations in the katG gene, which codes for the catalase-peroxidase enzyme that converts the prodrug isoniazid into its active form. The capacity of katG to activate isoniazid is reduced or eliminated by mutations, making the medication ineffective against Mycobacterium tuberculosis (Mtb)
   - **Resistance to Rifampicin (RIF)**: Mutations in the rpoB gene, which codes for the RNA polymerase beta subunit, frequently lead to RIF resistance. Because of these changes, rifampicin cannot bind to

its intended target and cannot block RNA production in Mtb.

2. **Mechanisms of Fluoroquinolone Resistance**
   - DNA gyrase and topoisomerase IV, crucial enzymes involved in DNA replication and repair, are the targets of fluoroquinolones like levofloxacin and moxifloxacin. Mutations in the genes gyrA and gyrB, which encode DNA gyrase subunits, are usually the cause of resistance. These alterations change the drug's binding site, which lessens its efficacy against Mtb.

3. **Resistance to Second-Line Injectable Drugs**
   - Second-line injectable medications that interfere with Mtb protein synthesis include amikacin, kanamycin, and capreomycin. These medications target the 30S ribosomal subunit. Genes that impact drug binding or absorption, such as eis (enhanced intracellular survival protein) and rrs (which encodes the 16S rRNA), are frequently mutated in resistance to these medications.

4. **Efflux Pumps and Drug Efflux**
   - Mycobacteria have efflux pumps, which aggressively move medications out of the cell, lowering drug concentrations within and fostering resistance. Genes like iniA, iniB, and others encode efflux pumps, which, when mutated or overexpressed, increase the efflux of medications like aminoglycosides and fluoroquinolones.

5. **Biofilm Formation and Persister Cells**
   - Mtb is capable of forming biofilms, which are collections of bacteria covered in extracellular matrix and shielded from antibiotics and host immunological responses. Bacteria go into a persister state within biofilms, which is marked by a decrease in metabolic activity and an increase in resistance to antibiotics. Because they may withstand antibiotic exposure and then reactivate infection, persister cells may play a role in the emergence of drug resistance.

6. **Horizontal Gene Transfer and Acquired Resistance**
   - Mtb can obtain resistance genes from environmental sources or from other bacteria through the process of horizontal gene transfer. Drug-resistant characteristics may spread quickly across Mtb populations as a result of this mechanism, making treatment and control efforts more difficult.[9,10,11,12]

DIAGNOSTIC CHALLENGES

A number of different factors make it difficult to diagnose extensively drug-resistant tuberculosis (XDR-TB) accurately and in a timely manner.

1. **Complexity of Drug Resistance Profiles**
   - Fluoroquinolones, at least one second-line injectable medication (amikacin, kanamycin, or capreomycin), and resistance to first-line medications (rifampicin and isoniazid) characterize XDR-TB. Comprehensive drug susceptibility testing (DST), which is technically complex and might not be available in all circumstances, is necessary to determine this resistance profile. Conventional techniques, such as phenotypic DST, can be inaccurate in detecting all resistance mutations and are sluggish (requiring weeks to get data).

2. **Limited Access to DST Facilities**
   - Many areas, particularly those with low resources, lack labs capable of doing DST on fluoroquinolones and second-line medications. This restriction impedes the timely identification and start of the proper therapy, which helps XDR-TB spread throughout communities.

3. **Sampling Challenges**
   - It can be challenging to collect sufficient and high-quality biological specimens (such as sputum samples) for DST and culture, particularly in patients with extrapulmonary or smear-negative TB. Inadequate sampling methods or low-quality specimens might provide false-negative findings, which can postpone diagnosis and treatment.

4. **Diagnostic Delays and Treatment Initiation**
   - It may take a while for the DST to confirm the diagnosis of XDR-TB, which might mean that people go untreated or receive insufficient care. Postponing the start of therapy not only deteriorates the results for each patient but also raises the possibility of transmission throughout communities.

5. **Co-infection with HIV and Other Comorbidities**
   - Comorbid diseases including HIV/AIDS, diabetes, or malnutrition are common in patients with XDR-TB, which might make diagnosis and treatment results more difficult. Because of immune suppression and unusual clinical manifestations, HIV co-infection in particular can affect the course of tuberculosis (TB), the effectiveness of therapy, and the precision of diagnostic testing.

6. **High Cost of Diagnosis and Treatment**
   - In low-resource settings, diagnostic testing for XDR-TB, particularly those utilizing genetic and molecular techniques, may be prohibitively costly. Drug-sensitive TB is far less expensive to treat than XDR-TB, which presents financial difficulties for healthcare systems as well as patients.

7. **Emergence of Pre-extensively Drug-Resistant TB (Pre-XDR-TB)**
   - Pre-XDR-TB describes TB strains that are resistant to isoniazid and rifampicin in addition to

fluoroquinolones and second-line injectable medications. Diagnostic efforts are further complicated by the requirement for better monitoring and access to extensive DST in order to detect and manage Pre-XDR-TB strains.

8. **Quality Assurance and Laboratory Standards**
   - Effective tuberculosis control depends on ensuring the accuracy and consistency of DST findings across various laboratories and environments. Minimizing diagnostic mistakes and ensuring proper treatment regimens need quality assurance processes and adherence to international standards.

9. **Public Health Implications and Surveillance**
   - Effective public health actions, such as contact tracing, infection control measures, and focused treatment strategies, depend on a timely and correct diagnosis of XDR-TB. These attempts may be thwarted by inadequate diagnostic capability, which might result in continuous transmission and outbreaks.[13,14,15,16]

TREATMENT OUTCOMES AND PROGNOSIS IN XDR TB CASES

Because it is resistant to several first- and second-line medications, extensively drug-resistant tuberculosis (XDR TB) presents substantial therapeutic problems. The prognosis and results of treatment for instances with XDR TB might differ based on many factors.

1. **Severity and Spread of Resistance**: XDR TB is characterized by resistance to a fluoroquinolone, a second-line injectable medication, and at least four of the main anti-TB medications, such as isoniazid and rifampicin. Treatment becomes more challenging the more widespread the resistance pattern is.
2. **Treatment Regimen**: Generally, a mix of antibiotics is used for therapy, frequently incorporating medications that are more hazardous and less effective than conventional TB therapies. The treatment plan is frequently extended (up to 18–24 months) and may entail taking many drugs every day.
3. **Patient Factors**: A patient's capacity to accept medicine, any underlying medical issues, immunological state, and general health all affect how well a treatment plan works.
4. **Access to Care and Treatment Adherence**: For optimal results, patients must have access to expert care, get regular monitoring, and strictly follow their prescribed course of action. Treatment failure and the emergence of new resistance might result from non-adherence.
5. **Prognosis**: There is a cautious outlook for XDR TB. Because treating drug-resistant forms of tuberculosis can be more difficult, treatment outcomes are less successful than with drug-sensitive strains. Higher death rates are possible, particularly in situations involving severe illness or in individuals with weakened immune systems.
6. **New Treatments and Strategies**: Investigations into novel antibiotics and approaches to treating drug-resistant tuberculosis persist, encompassing abbreviated treatment plans and novel drug amalgamations. Future results might be improved by these advances.[17,18,19]

CURRENT TREATMENT PROTOCOLS FOR XDR TB

Because the bacterium that causes extensively drug-resistant tuberculosis (XDR TB) is resistant to several common TB treatments, the treatment procedures for this kind of tuberculosis are complicated and usually entail numerous medications. The following are the main elements of the XDR TB treatment regimens in use today.

1. **Individualized Treatment Plans**: The findings of drug susceptibility testing (DST), which show which medications the bacteria are susceptible to, are used to customize treatment regimens. This aids in creating a routine that has the best chance of working.
2. **Drug Regimens**: A mix of antibiotics, comprising some of the following classes, is frequently included of the prescription for XDR TB.
   - **Group A**: Oral medications that are more recent and have efficacy against drug-resistant tuberculosis, such as bedaquiline, linezolid, clofazimine, and delamanid.
   - **Group B**: Injectable medications, such as capreomycin, kanamycin, or amikacin; nevertheless, XDR TB is frequently associated with injectable resistance.
   - **Group C**: Older second-line medications with potential lingering efficacy, such as ethionamide, cycloserine, and para-aminosalicylic acid (PAS).
3. **Duration**: The course of treatment is extended; it often lasts 18 to 24 months or longer. The patient's reaction to therapy, the severity of the illness, and their drug tolerance are some of the factors that determine how long the course will take.
4. **Monitoring**: To evaluate the effectiveness of a treatment, control side effects, and stop additional resistance, close monitoring is necessary. This covers routine imaging investigations, lab testing, and clinical assessments.
5. **Adherence Support**: It's critical to make sure patients follow their treatment plan. This might entail giving patients and their families information and assistance in addition to directly observed treatment (DOT), in which medical professionals watch patients take their prescriptions.
6. **Supportive Care**: In order to control problems and enhance treatment results, patients with XDR TB frequently need supportive care. This covers treating additional medical illnesses, managing the negative

effects of medications, and providing dietary assistance.

7. **Infection Control**: To stop the spread of XDR TB in medical facilities and the population, stringent infection control procedures are required. This include keeping infected patients apart, providing enough air, and having healthcare personnel wear personal protective equipment.
8. **Research and Clinical Trials**: To enhance results, shorten treatment time, and lessen toxicity, current research and clinical studies are investigating novel medications and treatment plans for XDR TB.

The management of XDR TB necessitates a multidrug regimen customized to each patient's drug susceptibility profile, an extended course of therapy, close monitoring, assistance with adherence, and stringent infection control measures. Working together, public health officials, academics, and healthcare practitioners can successfully address the issues presented by this complicated type of TB.[20,21,22]

CHALLENGES IN CLINICAL IMPLEMENTATION OF NEW THERAPIES

Many obstacles stand in the way of the practical use of novel treatments for extensively drug-resistant tuberculosis (XDR TB), which may have an impact on their uptake and efficacy:

1. **Drug Access and Availability**: Access to newly authorized treatments for XDR TB may be limited in some areas, especially in low- and middle-income nations where the prevalence of TB is highest. Access to these medicines may be restricted by factors including supply chain management, cost, and regulatory approval procedures.
2. **Diagnostic Challenges**: Starting the right treatment for XDR TB requires an accurate and prompt diagnosis. However, diagnostic testing for drug-resistant tuberculosis may not be readily accessible or reasonably priced, particularly in environments with low resources. This raises the possibility of transmission and postpones the start of treatment.
3. **Complex Treatment Regimens**: Novel treatments for XDR TB frequently entail intricate plans that call for several prescription drugs and a protracted course of treatment. Patients may find it difficult to follow these regimens, particularly if their drugs have severe adverse effects or call for unusual administration techniques.
4. **Monitoring and Management of Side Effects**: Certain new medications for XDR TB may have unusual toxicities or side effects that call for careful monitoring and handling. To manage these intricacies and offer patients complete treatment, healthcare systems must be outfitted.
5. **Healthcare Infrastructure and Human Resources**: Robust systems for patient follow-up and support, as well as laboratory facilities for drug susceptibility testing, are necessary for the effective implementation of new therapies. Trained healthcare personnel can also be used for treatment administration and monitoring.
6. **Data and Evidence Generation**: To guide clinical practice and policy choices, real-world data on the efficacy and safety of novel medicines for XDR TB must be generated. On the other hand, carrying out post-marketing surveillance and clinical studies in various contexts can be resource- and logistically-demanding.
7. **Integration with Existing Programs**: Collaboration between several stakeholders, including as government health departments, non-governmental organizations, and foreign agencies, is necessary to integrate novel medicines into current TB control programs and healthcare delivery systems. In this way, novel treatments are certain to reach the people who require them the most.
8. **Sustainability and Funding**: Long-term success depends on securing stable financing for operational research, capacity-building programs, and the acquisition of novel medicines. Treatment continuity may be jeopardized by reliance on outside financial sources and donors.[23,24,25]

FUTURE DIRECTIONS

The future of treating extensively drug-resistant tuberculosis (XDR TB) is expected to center on a number of important areas in order to enhance overall control, diagnosis, treatment, and prevention.

1. **Development of New Drugs and Treatment Regimens**
   - **Novel Antibiotics**: To increase treatment choices and boost efficacy, ongoing research and development of novel antibiotics with action against drug-resistant tuberculosis, especially XDR tuberculosis, is needed.
   - **Shorter and Simplified Regimens**: Research is being done to find shorter, less complicated treatment plans that work well for treating XDR TB, shortening treatment times, and enhancing adherence.

2. **Improved Diagnostics**
   - **Point-of-Care Tests**: Creation and implementation of quick, precise, and reasonably priced point-of-care diagnostic tests for drug-resistant tuberculosis, particularly XDR tuberculosis, to facilitate early identification and timely start of suitable treatment
   - **Molecular and Genetic Tools**: Technological developments in molecular and genetic testing have improved drug susceptibility testing's accuracy and speed, enabling more individualized treatment plans.

3. **Vaccination Strategies**
   - **New TB Vaccines**: To improve preventive efforts and lower the worldwide incidence of TB, particularly XDR TB, ongoing research is being done on novel TB vaccine candidates, including those that target drug-resistant strains.

4. **Digital Health and Telemedicine**
   - **Telemedicine and Digital Tools**: Integration of digital health technology and telemedicine platforms to enhance patient access to tuberculosis care, provide remote patient monitoring during treatment, and assist healthcare practitioners in environments with limited resources.

5. **Health Systems Strengthening**
   - **Capacity Building**: To guarantee the efficient delivery of TB prevention, diagnostic, and treatment services, especially in high-burden regions, strengthen the workforce, laboratory systems, and healthcare infrastructure.
   - **Integration of TB Services**: To maximize resource allocation and enhance patient outcomes, TB care should be integrated with other health initiatives, such as HIV/AIDS and maternal health.

6. **Addressing Social Determinants of Health**
   - **Social Support**: Putting social support interventions into practice to address socioeconomic issues including poverty, stigma, and access to healthcare services that affect treatment results and the spread of tuberculosis.

7. **Global Collaboration and Financing**
   - **International Cooperation**: Persistent cooperation between nations, international organizations, donors, and stakeholders to secure political support, financial support, and resources for tuberculosis control initiatives, including the creation of new interventions and their research.
   - **Financial Sustainability**: Ensuring TB programs have long-term funding sources to enable intervention implementation and help the world reach its TB eradication goals.

8. **Monitoring, Evaluation, and Research**
   - **Research and Innovation**: Ongoing funding for operational research to analyze and improve implementation plans, track medication resistance patterns, and gauge the effect of actions on tuberculosis reduction.
   - **Surveillance Systems**: Enhancing TB surveillance systems to track advancements made toward the eradication of tuberculosis, identify new trends in drug resistance, and inform evidence-based policy choices.[26 to 30]

Achieving the ultimate aim of TB eradication worldwide and effectively defeating extensively drug-resistant tuberculosis may be accelerated by stakeholders by concentrating on these future paths and utilizing scientific, technological, and international partnership advancements.

CONCLUSION

One major obstacle to international attempts to eradicate tuberculosis is the establishment and spread of extensively drug-resistant tuberculosis (XDR-TB). The complex processes by which XDR-TB becomes resistant to several anti-tuberculosis medications have been clarified in this study, emphasizing genetic alterations and acquired resistance mechanisms as the main causes of treatment failure. Notwithstanding progress in comprehension, the management of XDR-TB nevertheless faces several obstacles, such as restricted diagnostic options, intricate therapy plans, and systemic healthcare limits. Prospective approaches to address XDR-TB in the future include the creation of quick molecular diagnostics for early drug resistance identification, investigation of new anti-tuberculosis drugs active against resistant strains, and application of patient-centered treatment plans. To overcome these obstacles and make significant progress toward worldwide tuberculosis control, cross-sector cooperation and ongoing investment in R&D are crucial.

In the end, treating medication resistance in XDR-TB necessitates an all-encompassing strategy that incorporates scientific advancements, fortifies healthcare institutions, and places a premium on fair access to high-quality care. By using these tactics, we may work to lessen the impact of XDR-TB, enhance treatment results, and get closer to the global elimination of tuberculosis as a hazard to public health.

REFERENCES

1. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med, 2015 Apr 27; 5(9): a017863.
2. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, Becerra M, Benedetti A, Burgos M, Centis R, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. *PLoS Med* 9: e1001300.
3. Cegielski JP. 2010. Extensively drug-resistant tuberculosis: "There must be some kind of way out of here". *Clin Infect Dis*, 50: S195–S200.
4. Vishwakarma D, Gaidhane A, Sahu S, Rathod AS. Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review. Cureus, 2023 Dec 9; 15(12): e50222.
5. CDCTB: tuberculosis (TB) - drug-resistant TB. centers for disease control and prevention. [Feb; 2023]. https://www.cdc.gov/tb/topic/drtb/default.htm
6. Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol, 2022 Sep 23; 12: 943545.
7. Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel), 2014 Jul 2; 3(3): 317-40.
8. Blanchard J.S. Molecular mechanisms of drug resistance in *Mycobacterium tuberculosis*. *Annu. Rev. Biochem*, 1996; 65: 215–239.

9. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis, 2011 Mar; 17(3): 510-3.
10. Harrison GA, Cho K, Wang ER, Sarkar S, Almqvist F, Patti GJ, Stallings CL. Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug resistant *Mycobacterium tuberculosis*. bioRxiv [Preprint], 2023 Feb 7: 2023.02.06.527416.
11. Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother, 2018 May 1; 73(5): 1138-1151.
12. Singh S, Datta S, Narayanan KB, Rajnish KN. Bacterial exo-polysaccharides in biofilms: role in antimicrobial resistance and treatments. J Genet Eng Biotechnol, 2021 Sep 23; 19(1): 140.
13. Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol, 2018 Oct; 42: 7-15.
14. Pillay S, Steingart KR, Davies GR, Chaplin M, De Vos M, Schumacher SG, Warren R, Theron G. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev, 2022 May 18; 5(5): CD014841.
15. Lorenc A, Ananthavarathan P, Lorigan J, Jowata M, Brook G, Banarsee R. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. London J Prim Care (Abingdon), 2014; 6(4): 84-90.
16. Ridderhof JC, van Deun A, Kam KM, Narayanan PR, Aziz MA. Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ, 2007 May; 85(5): 354-9.
17. O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Jr. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis, 2013 Mar; 19(3): 416-24.
18. Shin S, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, et al. 2006. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. *Int J Tuberc Lung Dis*, 10: 402–408.
19. Girum, T., Tariku, Y., & Dessu, S. (2017). Survival Status and Treatment Outcome of Multidrug Resistant Tuberculosis (MDR-TB) among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia: A Retrospective Cohort Study. *Annals of Medical and Health Sciences Research*, *7*.
20. Menzies R. Multidrug-resistant tuberculosis treatment regimens and patient outcomes: an Individual Patient Data (IPD) meta-analysis of 9153 patients. PLoS Medicine, 2012 August 28.
21. Sturdy A, Goodman A, Jose RJ, Loyse A, O'Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011; 66(8): 1815–1820.
22. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 1994; 263(5144): 227–30.
23. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J., 2014 Jul; 44(1): 23-63.
24. Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol, 2018 Oct; 42: 7-15.
25. Falzon D., Schunemann H.J., Harausz E., Gonzalez-Angulo L., Lienhardt C., Jaramillo E., Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur Respir J.*, 2017; 49.
26. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med., 2014 Apr; 2(4): 321-38.
27. Singh V, Chibale K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Acc Chem Res, 2021 May 18; 54(10): 2361-2376.
28. Mancuso G, Midiri A, De Gaetano S, Ponzo E, Biondo C. Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen *Mycobacterium tuberculosis*. *Microorganisms*, 2023; 11(9): 2277.
29. Nguyen TNA, Anton-Le Berre V, Bañuls AL, Nguyen TVA. Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review. Front Microbiol, 2019 Apr 16; 10: 794.
30. Lönnroth K, Migliori GB. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J., 2015 Apr; 45(4): 928-52.